Logotipo del repositorio
Logotipo del repositorio
 

Advanced Glycation End Products: New Clinical and Molecular Perspectives

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorSalazar, Juan
dc.contributor.authorNavarro, Carla
dc.contributor.authorOrtega, Ángel
dc.contributor.authorNava, Manuel
dc.contributor.authorMorillo, Daniela
dc.contributor.authorTorres, Wheeler
dc.contributor.authorHernández, Marlon
dc.contributor.authorCabrera, Mayela
dc.contributor.authorAngarita, Lissé
dc.contributor.authorOrtiz, Rina
dc.contributor.authorChacín, Maricarmen
dc.contributor.authorD'Marco, Luis
dc.contributor.authorBermúdez, Valmore
dc.date.accessioned2021-09-13T23:13:59Z
dc.date.available2021-09-13T23:13:59Z
dc.date.issued2021
dc.description.abstractDiabetes mellitus (DM) is considered one of the most massive epidemics of the twenty-first century due to its high mortality rates caused mainly due to its complications; therefore, the early identification of such complications becomes a race against time to establish a prompt diagnosis. The research of complications of DM over the years has allowed the development of numerous alternatives for diagnosis. Among these emerge the quantification of advanced glycation end products (AGEs) given their increased levels due to chronic hyperglycemia, while also being related to the induction of different stress-associated cellular responses and proinflammatory mechanisms involved in the progression of chronic complications of DM. Additionally, the investigation for more valuable and safe techniques has led to developing a newer, noninvasive, and effective tool, termed skin fluorescence (SAF). Hence, this study aimed to establish an update about the molecular mechanisms induced by AGEs during the evolution of chronic complications of DM and describe the newer measurement techniques available, highlighting SAF as a possible tool to measure the risk of developing DM chronic complications.eng
dc.format.mimetypepdfspa
dc.identifier.doihttps://doi.org/10.3390/ijerph18147236
dc.identifier.issn16604601
dc.identifier.urihttps://hdl.handle.net/20.500.12442/8360
dc.language.isoengeng
dc.publisherMDPIeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceInternational Journal of Enviromental Research and Public Healtheng
dc.sourceVol. 18 N° 14 (2021)
dc.subjectadvanced glycation end productseng
dc.subjectdiabetes mellituseng
dc.subjectchronic complicationseng
dc.subjectskin fluorescenceeng
dc.titleAdvanced Glycation End Products: New Clinical and Molecular Perspectiveseng
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesKerner, W.; Brückel, J. German Diabetes Association Definition, Classification and Diagnosis of Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes 2014, 122, 384–386.eng
dcterms.referencesZimmet, P.; Alberti, K.G.; Magliano, D.J.; Bennett, P.H. Diabetes Mellitus Statistics on Prevalence and Mortality: Facts and Fallacies. Nat. Rev. Endocrinol. 2016, 12, 616–622.eng
dcterms.referencesInternational Diabetes Federation (IDF). IDF Diabetes Atlas, 7th ed.; International Diabetes Federation: Brussels, Belgium, 2015; Available online: https://www.desang.net/2017/11/idf-diabetes-atlas-7th-edition/ (accessed on 7 May 2021).eng
dcterms.referencesSingh, V.P.; Bali, A.; Singh, N.; Jaggi, A.S. Advanced Glycation End Products and Diabetic Complications. Korean J. Physiol. Pharm. 2014, 18, 1–14.eng
dcterms.referencesButalia, S.; Patel, A.B.; Johnson, J.A.; Ghali, W.A.; Rabi, D.M. Geographic Clustering of Acute Complications and Sociodemographic Factors in Adults with Type 1 Diabetes. Can. J. Diabetes 2017, 41, 132–137.eng
dcterms.referencesElgart, J.F.; Caporale, J.E.; Asteazarán, S.; De La Fuente, J.L.; Camilluci, C.; Brown, J.B.; González, C.D.; Gagliardino, J.J. Association between Socioeconomic Status, Type 2 Diabetes and Its Chronic Complications in Argentina. Diabetes Res. Clin. Pract. 2014, 104, 241–247.eng
dcterms.referencesShi, Y.; Vanhoutte, P.M. Macro- and Microvascular Endothelial Dysfunction in Diabetes. J. Diabetes 2017, 9, 434–449.eng
dcterms.referencesLoomis, S.J.; Chen, Y.; Sacks, D.B.; Christenson, E.S.; Christenson, R.H.; Rebholz, C.M.; Selvin, E. Cross-Sectional Analysis of AGE-CML, SRAGE, and EsRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort. Clin. Chem. 2017, 63, 980–989.eng
dcterms.referencesVélayoudom-Céphise, F.-L.; Rajaobelina, K.; Helmer, C.; Nov, S.; Pupier, E.; Blanco, L.; Hugo, M.; Farges, B.; Astrugue, C.; Gin, H.; et al. Skin Autofluorescence Predicts Cardio-Renal Outcome in Type 1 Diabetes: A Longitudinal Study. Cardiovasc. Diabetol. 2016, 15, 127.eng
dcterms.referencesThomas, M.C.; Woodward, M.; Neal, B.; Li, Q.; Pickering, R.; Marre, M.; Williams, B.; Perkovic, V.; Cooper, M.E.; Zoungas, S.; et al. Relationship between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults with Type 2 Diabetes. Diabetes Care 2015, 38, 1891–1897.eng
dcterms.referencesD’Alessandro, A.; Mirasole, C.; Zolla, L. Haemoglobin Glycation (Hb1Ac) Increases during Red Blood Cell Storage: A MALDI-TOF Mass-Spectrometry-Based Investigation. Vox Sang. 2013, 105, 177–180.eng
dcterms.referencesCho, Y.H.; Craig, M.E.; Januszewski, A.S.; Benitez-Aguirre, P.; Hing, S.; Jenkins, A.J.; Donaghue, K.C. Higher Skin Autofluorescence in Young People with Type 1 Diabetes and Microvascular Complications. Diabet. Med. 2017, 34, 543–550.eng
dcterms.referencesBotros, N.; Sluik, D.; van Waateringe, R.P.; de Vries, J.H.M.; Geelen, A.; Feskens, E.J.M. Advanced Glycation End-Products (AGEs) and Associations with Cardio-Metabolic, Lifestyle, and Dietary Factors in a General Population: The NQplus Study. Diabetes Metab. Res. Rev. 2017, 33.eng
dcterms.referencesUribarri, J.; Woodruff, S.; Goodman, S.; Cai, W.; Chen, X.; Pyzik, R.; Yong, A.; Striker, G.E.; Vlassara, H. Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet. J. Am. Diet. Assoc. 2010, 110, 911–916.eng
dcterms.referencesMondaca-Navarro, B.A.; Ávila-Villa, L.A.; González-Córdova, A.F.; López-Cervantes, J.; Sánchez-Machado, D.I.; Campas-Baypoli, O.N.; Rodríguez-Ramírez, R. Antioxidant and Chelating Capacity of Maillard Reaction Products in Amino Acid-Sugar Model Systems: Applications for Food Processing. J. Sci. Food Agric. 2017, 97, 3522–3529.eng
dcterms.referencesBrownlee, M.; Vlassara, H.; Cerami, A. Nonenzymatic Glycosylation and the Pathogenesis of Diabetic Complications. Ann. Intern. Med. 1984, 101, 527–537.eng
dcterms.referencesChu, F.L.; Yaylayan, V.A. Post-Schiff Base Chemistry of the Maillard Reaction: Mechanism of Imine Isomerization. Ann. N. Y. Acad. Sci. 2008, 1126, 30–37.eng
dcterms.referencesJohnson, K.L.; Williams, J.G.; Maleki, S.J.; Hurlburt, B.K.; London, R.E.; Mueller, G.A. Enhanced Approaches for Identifying Amadori Products: Application to Peanut Allergens. J. Agric. Food Chem. 2016, 64, 1406–1413.eng
dcterms.referencesBucala, R.; Model, P.; Cerami, A. Modification of DNA by Reducing Sugars: A Possible Mechanism for Nucleic Acid Aging and Age-Related Dysfunction in Gene Expression. Proc. Natl. Acad. Sci. USA 1984, 81, 105–109.eng
dcterms.referencesAnsari, N.A.; Moinuddin, null; Mir, A.R.; Habib, S.; Alam, K.; Ali, A.; Khan, R.H. Role of Early Glycation Amadori Products of Lysine-Rich Proteins in the Production of Autoantibodies in Diabetes Type 2 Patients. Cell Biochem. Biophys. 2014, 70, 857–865.eng
dcterms.referencesOlar, L.; Razvan, Ștefan; Berce, C.; Ciobanu, D.; Papuc, I. Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca. Vet. Med. 2015, 65, 358.eng
dcterms.referencesStirban, A.; Gawlowski, T.; Roden, M. Vascular Effects of Advanced Glycation Endproducts: Clinical Effects and Molecular Mechanisms. Mol. Metab. 2014, 3, 94–108.eng
dcterms.referencesMacías-Cervantes, M.H.; Rodríguez-Soto, J.M.D.; Uribarri, J.; Díaz-Cisneros, F.J.; Cai, W.; Garay-Sevilla, M.E. Effect of an Advanced Glycation End Product-Restricted Diet and Exercise on Metabolic Parameters in Adult Overweight Men. Nutrition 2015, 31, 446–451.eng
dcterms.referencesUribarri, J.; Cai, W.; Ramdas, M.; Goodman, S.; Pyzik, R.; Chen, X.; Zhu, L.; Striker, G.E.; Vlassara, H. Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes: Potential Role of AGER1 and SIRT1. Diabetes Care 2011, 34, 1610–1616.eng
dcterms.referencesAngoorani, P.; Ejtahed, H.-S.; Mirmiran, P.; Mirzaei, S.; Azizi, F. Dietary Consumption of Advanced Glycation End Products and Risk of Metabolic Syndrome. Int. J. Food Sci. Nutr. 2016, 67, 170–176eng
dcterms.referencesSaha, A.; Poojary, P.; Chan, L.; Chauhan, K.; Nadkarni, G.; DO, S.C.; Uribarri, J. Increased Odds of Metabolic Syndrome with Consumption of High Dietary Advanced Glycation End Products in Adolescents. Diabetes Metab. 2017, 43, 469–471.eng
dcterms.referencesLv, X.; Lv, G.-H.; Dai, G.-Y.; Sun, H.-M.; Xu, H.-Q. Food-Advanced Glycation End Products Aggravate the Diabetic Vascular Complications via Modulating the AGEs/RAGE Pathway. Chin. J. Nat. Med. 2016, 14, 844–855.eng
dcterms.referencesLi, Z.; Wang, G.; Zhu, Y.-J.; Li, C.-G.; Tang, Y.-Z.; Jiang, Z.-H.; Yang, M.; Ni, C.-L.; Chen, L.-M.; Niu, W.-Y. The Relationship between Circulating Irisin Levels and Tissues AGE Accumulation in Type 2 Diabetes Patients. Biosci. Rep. 2017, 37.eng
dcterms.referencesChawla, D.; Bansal, S.; Banerjee, B.D.; Madhu, S.V.; Kalra, O.P.; Tripathi, A.K. Role of Advanced Glycation End Product (AGE)-Induced Receptor (RAGE) Expression in Diabetic Vascular Complications. Microvasc. Res. 2014, 95, 1–6.eng
dcterms.referencesXue, J.; Ray, R.; Singer, D.; Böhme, D.; Burz, D.S.; Rai, V.; Hoffmann, R.; Shekhtman, A. The Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal-Derived AGEs. Biochemistry 2014, 53, 3327–3335.eng
dcterms.referencesHofmann, M.A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; et al. RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides. Cell 1999, 97, 889–901.eng
dcterms.referencesGrimm, S.; Ott, C.; Hörlacher, M.; Weber, D.; Höhn, A.; Grune, T. Advanced-Glycation-End-Product-Induced Formation of Immunoproteasomes: Involvement of RAGE and Jak2/STAT1. Biochem. J. 2012, 448, 127–139.eng
dcterms.referencesGao, Z.Q.; Yang, C.; Wang, Y.Y.; Wang, P.; Chen, H.L.; Zhang, X.D.; Liu, R.; Li, W.L.; Qin, X.J.; Liang, X.; et al. RAGE Upregulation and Nuclear Factor-KappaB Activation Associated with Ageing Rat Cardiomyocyte Dysfunction. Gen. Physiol. Biophys. 2008, 27, 152–158.eng
dcterms.referencesGao, Z.Q.; Yang, C.; Wang, Y.Y.; Wang, P.; Chen, H.L.; Zhang, X.D.; Liu, R.; Li, W.L.; Qin, X.J.; Liang, X.; et al. RAGE Upregulation and Nuclear Factor-KappaB Activation Associated with Ageing Rat Cardiomyocyte Dysfunction. Gen. Physiol. Biophys. 2008, 27, 152–158.eng
dcterms.referencesOhashi, K.; Takahashi, H.K.; Mori, S.; Liu, K.; Wake, H.; Sadamori, H.; Matsuda, H.; Yagi, T.; Yoshino, T.; Nishibori, M.; et al. Advanced Glycation End Products Enhance Monocyte Activation during Human Mixed Lymphocyte Reaction. Clin. Immunol. 2010, 134, 345–353.eng
dcterms.referencesJin, X.; Yao, T.; Zhou, Z.; Zhu, J.; Zhang, S.; Hu, W.; Shen, C. Advanced Glycation End Products Enhance Macrophages Polarization into M1 Phenotype through Activating RAGE/NF-ΚB Pathway. Biomed. Res. Int. 2015, 2015, 732450.eng
dcterms.referencesJhun, J.; Lee, S.; Kim, H.; Her, Y.-M.; Byun, J.K.; Kim, E.-K.; Lee, S.K.; Cho, M.-L.; Choi, J.Y. HMGB1/RAGE Induces IL-17 Expression to Exaggerate Inflammation in Peripheral Blood Cells of Hepatitis B Patients. J. Transl. Med. 2015, 13.eng
dcterms.referencesBangert, A.; Andrassy, M.; Müller, A.-M.; Bockstahler, M.; Fischer, A.; Volz, C.H.; Leib, C.; Göser, S.; Korkmaz-Icöz, S.; Zittrich, S.; et al. Critical Role of RAGE and HMGB1 in Inflammatory Heart Disease. Proc. Natl. Acad. Sci. USA 2016, 113, E155–E164.eng
dcterms.referencesDetzen, L.; Cheng, B.; Chen, C.-Y.; Papapanou, P.N.; Lalla, E. Soluble Forms of the Receptor for Advanced Glycation Endproducts (RAGE) in Periodontitis. Sci. Rep. 2019, 9, 8170.eng
dcterms.referencesEgaña-Gorroño, L.; López-Díez, R.; Yepuri, G.; Ramirez, L.S.; Reverdatto, S.; Gugger, P.F.; Shekhtman, A.; Ramasamy, R.; Schmidt, A.M. Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models. Front. Cardiovasc. Med. 2020, 7, 37.eng
dcterms.referencesSchmidt, A.M. Soluble RAGEs Prospects for Treating & Tracking Metabolic and Inflammatory Disease. Vasc. Pharm. 2015, 72, 1–8.eng
dcterms.referencesFarhan, S.S.; Hussain, S.A. Advanced Glycation End Products (AGEs) and Their Soluble Receptors (SRAGE) as Early Predictors of Reno-Vascular Complications in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Metab. Syndr. Clin. Res. Rev. 2019, 13, 2457–2461.eng
dcterms.referencesGerrits, E.G.; Lutgers, H.L.; Kleefstra, N.; Graaff, R.; Groenier, K.H.; Smit, A.J.; Gans, R.O.; Bilo, H.J. Skin Autofluorescence: A Tool to Identify Type 2 Diabetic Patients at Risk for Developing Microvascular Complications. Diabetes Care 2008, 31, 517–521.eng
dcterms.referencesSun, H.; Yuan, Y.; Sun, Z. Update on Mechanisms of Renal Tubule Injury Caused by Advanced Glycation End Products. Biomed. Res. Int. 2016, 2016, e5475120.eng
dcterms.referencesZong, H.; Ward, M.; Madden, A.; Yong, P.H.; Limb, G.A.; Curtis, T.M.; Stitt, A.W. Hyperglycaemia-Induced pro-Inflammatory Responses by Retinal Müller Glia Are Regulated by the Receptor for Advanced Glycation End-Products (RAGE). Diabetologia 2010, 53, 2656–2666.eng
dcterms.referencesSato, K.; Tatsunami, R.; Yama, K.; Tampo, Y. Glycolaldehyde Induces Cytotoxicity and Increases Glutathione and Multidrug-Resistance-Associated Protein Levels in Schwann Cells. Biol. Pharm. Bull. 2013, 36, 1111–1117.eng
dcterms.referencesLu, Z.; Liu, N.; Wang, F. Epigenetic Regulations in Diabetic Nephropathy. J. Diabetes Res. 2017, 2017.eng
dcterms.referencesEspinel, E.; Agraz, I.; Ibernon, M.; Ramos, N.; Fort, J.; Serón, D. Renal Biopsy in Type 2 Diabetic Patients. J. Clin. Med. 2015, 4, 998.eng
dcterms.referencesChuang, P.Y.; Yu, Q.; Fang, W.; Uribarri, J.; He, J.C. Advanced Glycation Endproducts Induce Podocyte Apoptosis by Activation of the FOXO4 Transcription Factor. Kidney Int. 2007, 72, 965–976.eng
dcterms.referencesZhang, M.; Feng, L.; Zhu, M.; Gu, J.; Jiang, J.; Cheng, X.; Ding, S.; Wu, C.; Jia, X. The Anti-Inflammation Effect of Moutan Cortex on Advanced Glycation End Products-Induced Rat Mesangial Cells Dysfunction and High-Glucose-Fat Diet and Streptozotocin-Induced Diabetic Nephropathy Rats. J. Ethnopharmacol. 2014, 151, 591–600.eng
dcterms.referencesKi, H.-J.; Kim, S.Y.; Lee, S.H.; Moon, J.-Y.; Jeong, K.H.; Lee, T.W.; Ihm, C.G.; Kim, S.K.; Chung, J.-H.; Kang, S.W.; et al. Transforming Growth Factor-β Receptor 2 Gene Polymorphisms Are Associated with End-Stage Renal Disease. Kidney Res. Clin. Pract. 2015, 34, 93–97.eng
dcterms.referencesMiura, J.; Yamagishi, S.I.; Uchigata, Y.; Takeuchi, M.; Yamamoto, H.; Makita, Z.; Iwamoto, Y. Serum Levels of Non-Carboxymethyllysine Advanced Glycation Endproducts Are Correlated to Severity of Microvascular Complications in Patients with Type 1 Diabetes. J. Diabetes Complicat. 2003, 17, 16–21eng
dcterms.referencesLiu, J.; Huang, K.; Cai, G.-Y.; Chen, X.-M.; Yang, J.-R.; Lin, L.-R.; Yang, J.; Huo, B.-G.; Zhan, J.; He, Y.-N. Receptor for Advanced Glycation End-Products Promotes Premature Senescence of Proximal Tubular Epithelial Cells via Activation of Endoplasmic Reticulum Stress-Dependent P21 Signaling. Cell Signal 2014, 26, 110–121.eng
dcterms.referencesLi, Y.; Ma, W.; Xie, C.; Zhang, M.; Yin, X.; Wang, F.; Xu, J.; Shi, B. Identification of Genes and Signaling Pathways Associated with Diabetic Neuropathy Using a Weighted Correlation Network Analysis: A Consort Study. Medicine 2016, 95, e5443.eng
dcterms.referencesAraszkiewicz, A.; Gandecka, A.; Nowicki, M.; Uruska, A.; Malińska, A.; Kowalska, K.; Wierusz-Wysocka, B.; Zozulińska-Ziółkiewicz, D. Association between Small Fiber Neuropathy and Higher Skin Accumulation of Advanced Glycation End Products in Patients with Type 1 Diabetes. Pol. Arch. Med. Wewn. 2016, 126, 847–853.eng
dcterms.referencesDuran-Jimenez, B.; Dobler, D.; Moffatt, S.; Rabbani, N.; Streuli, C.H.; Thornalley, P.J.; Tomlinson, D.R.; Gardiner, N.J. Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in Diabetes. Diabetes 2009, 58, 2893–2903.eng
dcterms.referencesLoske, C.; Neumann, A.; Cunningham, A.M.; Nichol, K.; Schinzel, R.; Riederer, P.; Münch, G. Cytotoxicity of Advanced Glycation Endproducts Is Mediated by Oxidative Stress. J. Neur. Transm 1998, 105, 1005–1015.eng
dcterms.referencesYu, T.; Li, L.; Chen, T.; Liu, Z.; Liu, H.; Li, Z. Erythropoietin Attenuates Advanced Glycation Endproducts-Induced Toxicity of Schwann Cells in Vitro. Neurochem. Res. 2015, 40, 698–712.eng
dcterms.referencesGuitart, K.; Loers, G.; Schachner, M.; Kleene, R. Prion Protein Regulates Glutathione Metabolism and Neural Glutamate and Cysteine Uptake via Excitatory Amino Acid Transporter 3. J. Neurochem. 2015, 133, 558–571.eng
dcterms.referencesBus, S.A.; Haspels, R.; Busch-Westbroek, T.E. Evaluation and Optimization of Therapeutic Footwear for Neuropathic Diabetic Foot Patients Using In-Shoe Plantar Pressure Analysis. Diabetes Care 2011, 34, 1595–1600.eng
dcterms.referencesVouillarmet, J.; Maucort-Boulch, D.; Michon, P.; Thivolet, C. Advanced Glycation End Products Assessed by Skin Autofluorescence: A New Marker of Diabetic Foot Ulceration. Diabetes Technol. 2013, 15, 601–605.eng
dcterms.referencesAmerican Diabetes Association. Screening Guidelines for Diabetic Retinopathy: Clinical Guideline. Ophthalmology 1992, 99, 1626–1628.eng
dcterms.referencesFrank, R.N. Diabetic Retinopathy. N. Engl. J. Med. 2004, 350, 48–58.eng
dcterms.referencesTracey, M.L.; McHugh, S.M.; Fitzgerald, A.P.; Buckley, C.M.; Canavan, R.J.; Kearney, P.M. Trends in Blindness Due to Diabetic Retinopathy among Adults Aged 18-69years over a Decade in Ireland. Diabetes Res. Clin. Pract. 2016, 121, 1–8.eng
dcterms.referencesKowluru, R.A. Effect of Advanced Glycation End Products on Accelerated Apoptosis of Retinal Capillary Cells under in Vitro Conditions. Life Sci. 2005, 76, 1051–1060.eng
dcterms.referencesBringmann, A.; Pannicke, T.; Grosche, J.; Francke, M.; Wiedemann, P.; Skatchkov, S.N.; Osborne, N.N.; Reichenbach, A. Müller Cells in the Healthy and Diseased Retina. Prog. Retin. Eye Res. 2006, 25, 397–424.eng
dcterms.referencesCheng, L.; Bu, H.; Portillo, J.-A.C.; Li, Y.; Subauste, C.S.; Huang, S.S.; Kern, T.S.; Lin, F. Modulation of Retinal Müller Cells by Complement Receptor C5aR. Invest. Ophthalmol. Vis. Sci. 2013, 54, 8191–8198.eng
dcterms.referencesYamagishi, S.; Nakamura, K.; Matsui, T.; Sato, T.; Takeuchi, M. Potential Utility of Statins, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Diabetic Retinopathy. Med. Hypotheses 2006, 66, 1019–1021.eng
dcterms.referencesAI, J.; LIU, Y.; SUN, J.-H. Advanced Glycation End-Products Stimulate Basic Fibroblast Growth Factor Expression in Cultured Müller Cells. Mol. Med. Rep. 2013, 7, 16–20.eng
dcterms.referencesShimizu, F.; Sano, Y.; Haruki, H.; Kanda, T. Advanced Glycation End-Products Induce Basement Membrane Hypertrophy in Endoneurial Microvessels and Disrupt the Blood-Nerve Barrier by Stimulating the Release of TGF-β and Vascular Endothelial Growth Factor (VEGF) by Pericytes. Diabetologia 2011, 54, 1517–1526.eng
dcterms.referencesRubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W.; Grishman, A. New Type of Cardiomyopathy Associated with Diabetic Glomerulosclerosis. Am. J. Cardiol. 1972, 30, 595–602.eng
dcterms.referencesAbd-El Aziz, F.M.; Abdelghaffar, S.; Hussien, E.M.; Fattouh, A.M. Evaluation of Cardiac Functions in Children and Adolescents with Type 1 Diabetes. J. Cardiovasc. Ultrasound. 2017, 25, 12–19.eng
dcterms.referencesYang, Q.; Gao, H.; Dong, R.; Wu, Y.-Q. Sequential Changes of Endoplasmic Reticulum Stress and Apoptosis in Myocardial Fibrosis of Diabetes Mellitus-Induced Rats. Mol. Med. Rep. 2016, 13, 5037–5044.eng
dcterms.referencesNovoa, U.; Arauna, D.; Moran, M.; Nuñez, M.; Zagmutt, S.; Saldivia, S.; Valdes, C.; Villaseñor, J.; Zambrano, C.G.; Gonzalez, D.R. High-Intensity Exercise Reduces Cardiac Fibrosis and Hypertrophy but Does Not Restore the Nitroso-Redox Imbalance in Diabetic Cardiomyopathy. Oxid. Med. Cell Longev. 2017, 2017, 7921363.eng
dcterms.referencesCao, W.; Chen, J.; Chen, Y.; Chen, X.; Liu, P. Advanced Glycation End Products Promote Heart Failure through Inducing the Immune Maturation of Dendritic Cells. Appl. Biochem. Biotechnol. 2014, 172, 4062–4077.eng
dcterms.referencesZerif, E.; Maalem, A.; Gaudreau, S.; Guindi, C.; Ramzan, M.; Véroneau, S.; Gris, D.; Stankova, J.; Rola-Pleszczynski, M.; Mourad, W.; et al. Constitutively Active Stat5b Signaling Confers Tolerogenic Functions to Dendritic Cells of NOD Mice and Halts Diabetes Progression. J. Autoimmun. 2017, 76, 63–74.eng
dcterms.referencesAnzai, A.; Anzai, T.; Nagai, S.; Maekawa, Y.; Naito, K.; Kaneko, H.; Sugano, Y.; Takahashi, T.; Abe, H.; Mochizuki, S.; et al. Regulatory Role of Dendritic Cells in Postinfarction Healing and Left Ventricular Remodeling. Circulation 2012, 125, 1234–1245.eng
dcterms.referencesAnzai, A.; Anzai, T.; Nagai, S.; Maekawa, Y.; Naito, K.; Kaneko, H.; Sugano, Y.; Takahashi, T.; Abe, H.; Mochizuki, S.; et al. Regulatory Role of Dendritic Cells in Postinfarction Healing and Left Ventricular Remodeling. Circulation 2012, 125, 1234–1245.eng
dcterms.referencesGeisterfer-Lowrance, A.A.; Kass, S.; Tanigawa, G.; Vosberg, H.P.; McKenna, W.; Seidman, C.E.; Seidman, J.G. A Molecular Basis for Familial Hypertrophic Cardiomyopathy: A Beta Cardiac Myosin Heavy Chain Gene Missense Mutation. Cell 1990, 62, 999–1006.eng
dcterms.referencesHerrmann, K.L.; McCulloch, A.D.; Omens, J.H. Glycated Collagen Cross-Linking Alters Cardiac Mechanics in Volume-Overload Hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2003, 284, H1277–H1284.eng
dcterms.referencesWillemsen, S.; Hartog, J.W.L.; Hummel, Y.M.; van Ruijven, M.H.I.; van der Horst, I.C.C.; van Veldhuisen, D.J.; Voors, A.A. Tissue Advanced Glycation End Products Are Associated with Diastolic Function and Aerobic Exercise Capacity in Diabetic Heart Failure Patients. Eur. J. Heart Fail 2011, 13, 76–82.eng
dcterms.referencesFang, M.; Wang, J.; Li, S.; Guo, Y. Advanced Glycation End-Products Accelerate the Cardiac Aging Process through the Receptor for Advanced Glycation End-Products/Transforming Growth Factor-β-Smad Signaling Pathway in Cardiac Fibroblasts. Geriatr. Gerontol. Int. 2016, 16, 522–527.eng
dcterms.referencesKawashima, T.; Inuzuka, Y.; Okuda, J.; Kato, T.; Niizuma, S.; Tamaki, Y.; Iwanaga, Y.; Kawamoto, A.; Narazaki, M.; Matsuda, T.; et al. Constitutive SIRT1 Overexpression Impairs Mitochondria and Reduces Cardiac Function in Mice. J. Mol. Cell Cardiol. 2011, 51, 1026–1036.eng
dcterms.referencesGu, X.S.; Wang, Z.B.; Ye, Z.; Lei, J.P.; Li, L.; Su, D.F.; Zheng, X. Resveratrol, an Activator of SIRT1, Upregulates AMPK and Improves Cardiac Function in Heart Failure. Genet. Mol. Res. 2014, 13, 323–335.eng
dcterms.referencesYuan, Q.; Zhou, Q.-Y.; Liu, D.; Yu, L.; Zhan, L.; Li, X.-J.; Peng, H.-Y.; Zhang, X.-L.; Yuan, X.-C. Advanced Glycation End-Products Impair Na+/K+-ATPase Activity in Diabetic Cardiomyopathy: Role of the Adenosine Monophosphate-Activated Protein Kinase/Sirtuin 1 Pathway. Clin. Exp. Pharm. Physiol. 2014, 41, 127–133.eng
dcterms.referencesYan, D.; Luo, X.; Li, Y.; Liu, W.; Deng, J.; Zheng, N.; Gao, K.; Huang, Q.; Liu, J. Effects of Advanced Glycation End Products on Calcium Handling in Cardiomyocytes. CRD 2014, 129, 75–83.eng
dcterms.referencesNiggli, E. The Cardiac Sarcoplasmic Reticulum. Circ. Res. 2007, 100, 5–6.eng
dcterms.referencesFischer, T.H.; Herting, J.; Tirilomis, T.; Renner, A.; Neef, S.; Toischer, K.; Ellenberger, D.; Förster, A.; Schmitto, J.D.; Gummert, J.; et al. Ca2+/Calmodulin-Dependent Protein Kinase II and Protein Kinase A Differentially Regulate Sarcoplasmic Reticulum Ca2+ Leak in Human Cardiac Pathology. Circulation 2013, 128, 970–981.eng
dcterms.referencesMatsui, T.; Higashimoto, Y.; Nishino, Y.; Nakamura, N.; Fukami, K.; Yamagishi, S.-I. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy. Diabetes 2017, 66, 1683–1695.eng
dcterms.referencesde la Hoz, C.L.; Cheng, C.; Fernyhough, P.; Zochodne, D.W. A Model of Chronic Diabetic Polyneuropathy: Benefits from Intranasal Insulin Are Modified by Sex and RAGE Deletion. Am. J. Physiol.Endocrinol. Metab. 2017, 312, E407–E419.eng
dcterms.referencesYamagishi, S.-I.; Matsui, T. Pathologic Role of Dietary Advanced Glycation End Products in Cardiometabolic Disorders, and Therapeutic Intervention. Nutrition 2016, 32, 157–165.eng
dcterms.referencesMonnier, V.M.; Bautista, O.; Kenny, D.; Sell, D.R.; Fogarty, J.; Dahms, W.; Cleary, P.A.; Lachin, J.; Genuth, S. Skin Collagen Glycation, Glycoxidation, and Crosslinking Are Lower in Subjects with Long-Term Intensive versus Conventional Therapy of Type 1 Diabetes: Relevance of Glycated Collagen Products versus HbA1c as Markers of Diabetic Complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999, 48, 870–880.eng
dcterms.referencesMeerwaldt, R.; Links, T.; Graaff, R.; Thorpe, S.R.; Baynes, J.W.; Hartog, J.; Gans, R.; Smit, A. Simple Noninvasive Measurement of Skin Autofluorescence. Ann. N. Y. Acad. Sci. 2005, 1043, 290–298.eng
dcterms.referencesSiriopol, D.; Hogas, S.; Veisa, G.; Mititiuc, I.; Volovat, C.; Apetrii, M.; Onofriescu, M.; Busila, I.; Oleniuc, M.; Covic, A. Tissue Advanced Glycation End Products (AGEs), Measured by Skin Autofluorescence, Predict Mortality in Peritoneal Dialysis. Int. Urol. Nephrol. 2015, 47, 563–569.eng
dcterms.referencesWillemsen, S.; Hartog, J.W.L.; Heiner-Fokkema, M.R.; van Veldhuisen, D.J.; Voors, A.A. Advanced Glycation End-Products, a Pathophysiological Pathway in the Cardiorenal Syndrome. Heart Fail Rev. 2012, 17, 221–228.eng
dcterms.referencesZhang, Y.; Lapidos, K.A.; Gal-Moscovici, A.; Sprague, S.M.; Ameer, G.A. A Receptor-Based Bioadsorbent to Target Advanced Glycation End Products in Chronic Kidney Disease. Artif. Organs 2014, 38, 474–483.eng
dcterms.referencesHaddad, M.; Knani, I.; Bouzidi, H.; Berriche, O.; Hammami, M.; Kerkeni, M. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect. Dis. Markers 2016, 2016, 6248264.eng
dcterms.referencesMcNair, E.; Qureshi, M.; Prasad, K.; Pearce, C. Atherosclerosis and the Hypercholesterolemic AGE–RAGE Axis. Int. J. Angiol. 2016, 25, 110–116.eng
dcterms.referencesScheijen, J.L.J.M.; van de Waarenburg, M.P.H.; Stehouwer, C.D.A.; Schalkwijk, C.G. Measurement of Pentosidine in Human Plasma Protein by a Single-Column High-Performance Liquid Chromatography Method with Fluorescence Detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877, 610–614.eng
dcterms.referencesBird, I.M. High Performance Liquid Chromatography: Principles and Clinical Applications. BMJ 1989, 299, 783–787.eng
dcterms.referencesVogeser, M.; Parhofer, K.G. Liquid Chromatography Tandem-Mass Spectrometry (LC-MS/MS)--Technique and Applications in Endocrinology. Exp. Clin. Endocrinol. Diabetes 2007, 115, 559–570eng
dcterms.referencesWillemsen, S.; Hartog, J.W.L.; van Veldhuisen, D.J.; van der Meer, P.; Roze, J.F.; Jaarsma, T.; Schalkwijk, C.; van der Horst, I.C.C.; Hillege, H.L.; Voors, A.A. The Role of Advanced Glycation End-Products and Their Receptor on Outcome in Heart Failure Patients with Preserved and Reduced Ejection Fraction. Am. Heart J. 2012, 164, 742–749.eng
dcterms.referencesVivekanadan-Giri, A.; Wang, J.H.; Byun, J.; Pennathur, S. Mass Spectrometric Quantification of Amino Acid Oxidation Products Identifies Oxidative Mechanisms of Diabetic End-Organ Damage. Rev. Endocr. Metab. Disord. 2008, 9, 275–287.eng
dcterms.referencesPetrovic, R.; Futas, J.; Chandoga, J.; Jakus, V. Rapid and Simple Method for Determination of Nepsilon-(Carboxymethyl)Lysine and Nepsilon-(Carboxyethyl)Lysine in Urine Using Gas Chromatography/Mass Spectrometry. Biomed. Chromatogr. 2005, 19, 649–654.eng
dcterms.referencesThornalley, P.J. Measurement of Protein Glycation, Glycated Peptides, and Glycation Free Adducts. Perit. Dial. Int. 2005, 25, 522–533.eng
dcterms.referencesMaciel, E.; da Silva, R.N.; Simões, C.; Melo, T.; Ferreira, R.; Domingues, P.; Domingues, M.R.M. Liquid Chromatography-Tandem Mass Spectrometry of Phosphatidylserine Advanced Glycated End Products. Chem. Phys. Lipids 2013, 174, 1–7.eng
dcterms.referencesPerkins, B.A.; Rabbani, N.; Weston, A.; Ficociello, L.H.; Adaikalakoteswari, A.; Niewczas, M.; Warram, J.; Krolewski, A.S.; Thornalley, P. Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes. PLoS ONE 2012, 7, e35655.eng
dcterms.referencesJaisson, S.; Souchon, P.-F.; Desmons, A.; Salmon, A.-S.; Delemer, B.; Gillery, P. Early Formation of Serum Advanced Glycation End-Products in Children with Type 1 Diabetes Mellitus: Relationship with Glycemic Control. J. Pediatr. 2016, 172, 56–62.eng
dcterms.referencesMeerwaldt, R.; Graaff, R.; Oomen, P.H.N.; Links, T.P.; Jager, J.J.; Alderson, N.L.; Thorpe, S.R.; Baynes, J.W.; Gans, R.O.B.; Smit, A.J. Simple Non-Invasive Assessment of Advanced Glycation Endproduct Accumulation. Diabetologia 2004, 47, 1324–1330.eng
dcterms.referencesHricik, D.E.; Wu, Y.C.; Schulak, A.; Friedlander, M.A. Disparate Changes in Plasma and Tissue Pentosidine Levels after Kidney and Kidney-Pancreas Transplantation. Clin. Transpl. 1996, 10, 568–573.eng
dcterms.referencesMonnier, V.M.; Sell, D.R.; Strauch, C.; Sun, W.; Lachin, J.M.; Cleary, P.A.; Genuth, S. The Association between Skin Collagen Glucosepane and Past Progression of Microvascular and Neuropathic Complications in Type 1 Diabetes. J. Diabetes Complicat. 2013, 27, 141–149.eng
dcterms.referencesJanuszewski, A.S.; Sachithanandan, N.; Karschimkus, C.; O’Neal, D.N.; Yeung, C.K.; Alkatib, N.; Jenkins, A.J. Non-Invasive Measures of Tissue Autofluorescence Are Increased in Type 1 Diabetes Complications and Correlate with a Non-Invasive Measure of Vascular Dysfunction. Diabet. Med. 2012, 29, 726–733eng
dcterms.referencesGenuth, S.; Sun, W.; Cleary, P.; Sell, D.R.; Dahms, W.; Malone, J.; Sivitz, W.; Monnier, V.M. Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes. Diabetes 2005, 54, 3103–3111.eng
dcterms.referencesvan der Heyden, J.C.; Birnie, E.; Mul, D.; Bovenberg, S.; Veeze, H.J.; Aanstoot, H.-J. Increased Skin Autofluorescence of Children and Adolescents with Type 1 Diabetes despite a Well-Controlled HbA1c: Results from a Cohort Study. BMC Endocr. Disord. 2016, 16, 49.eng
dcterms.referencesvan Waateringe, R.P.; Slagter, S.N.; van der Klauw, M.M.; van Vliet-Ostaptchouk, J.V.; Graaff, R.; Paterson, A.D.; Lutgers, H.L.; Wolffenbuttel, B.H.R. Lifestyle and Clinical Determinants of Skin Autofluorescence in a Population-Based Cohort Study. Eur. J. Clin. Investig. 2016, 46, 481–490.eng
dcterms.referencesRajaobelina, K.; Helmer, C.; Vélayoudom-Céphise, F.-L.; Nov, S.; Farges, B.; Pupier, E.; Blanco, L.; Hugo, M.; Gin, H.; Rigalleau, V. Progression of Skin Autofluorescence of AGEs over 4 Years in Patients with Type 1 Diabetes. Diabetes/Metab. Res. Rev. 2017, 33, e2917.eng
dcterms.referencesKouidrat, Y.; Zaitouni, A.; Amad, A.; Diouf, M.; Desailloud, R.; Loas, G.; Lalau, J.-D. Skin Autofluorescence (a Marker for Advanced Glycation End Products) and Erectile Dysfunction in Diabetes. J. Diabetes Complicat. 2017, 31, 108–113.eng
dcterms.referencesTemma, J.; Matsuhisa, M.; Horie, T.; Kuroda, A.; Mori, H.; Tamaki, M.; Endo, I.; Aihara, K.; Abe, M.; Matsumoto, T. Non-Invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes. J. Med. Investig. 2015, 62, 126–129.eng
dcterms.referencesVerzijl, N.; DeGroot, J.; Thorpe, S.R.; Bank, R.A.; Shaw, J.N.; Lyons, T.J.; Bijlsma, J.W.; Lafeber, F.P.; Baynes, J.W.; TeKoppele, J.M. Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products. J. Biol. Chem. 2000, 275, 39027–39031.eng
dcterms.referencesSugisawa, E.; Miura, J.; Iwamoto, Y.; Uchigata, Y. Skin Autofluorescence Reflects Integration of Past Long-Term Glycemic Control in Patients with Type 1 Diabetes. Diabetes Care 2013, 36, 2339–2345.eng
dcterms.referencesWang, C.-C.; Wang, Y.-C.; Wang, G.-J.; Shen, M.-Y.; Chang, Y.-L.; Liou, S.-Y.; Chen, H.-C.; Lee, A.-S.; Chang, K.-C.; Chen, W.-Y.; et al. Skin Autofluorescence Is Associated with Inappropriate Left Ventricular Mass and Diastolic Dysfunction in Subjects at Risk for Cardiovascular Disease. Cardiovasc. Diabetol. 2017, 16, 15.eng
dcterms.referencesKoetsier, M.; Nur, E.; Chunmao, H.; Lutgers, H.L.; Links, T.P.; Smit, A.J.; Rakhorst, G.; Graaff, R. Skin Color Independent Assessment of Aging Using Skin Autofluorescence. Opt. Express 2010, 18, 14416–14429. [CrossRef]spa
dcterms.referencesBrenner, M.; Hearing, V.J. The Protective Role of Melanin Against UV Damage in Human Skin. Photochem. Photobiol. 2008, 84, 539–549. [CrossRef]eng
dcterms.referencesBáez, E.A.; Shah, S.; Felipe, D.; Maynard, J.; Chalew, S. Correlation of Advanced Glycation Endproducts Estimated From Skin Fluorescence in First-Degree Relatives. J. Diabetes Sci. Technol. 2014, 9, 278–281. [CrossRef]eng
dcterms.referencesNenna, A.; Nappi, F.; Avtaar Singh, S.S.; Sutherland, F.W.; Di Domenico, F.; Chello, M.; Spadaccio, C. Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Res. Cardiovasc. Med. 2015, 4. [CrossRef]eng
dcterms.referencesPrasad, C.; Davis, K.E.; Imrhan, V.; Juma, S.; Vijayagopal, P. Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification. Am. J. Lifestyle Med. 2019, 13, 384–404. [CrossRef] [PubMed]eng
dcterms.referencesvan Waateringe, R.P.; Mook-Kanamori, M.J.; Slagter, S.N.; van der Klauw, M.M.; van der Vliet-Ostaptchouk, J.V.; Graaff, R.; Lutgers, H.L.; Suhre, K.; Selim, M.M.E.-D.; Mook-Kanamori, D.O.; et al. The Association between Various Smoking Behaviors, Cotinine Biomarkers and Skin Autofluorescence, a Marker for Advanced Glycation End Product Accumulation. PLoS ONE 2017, 12, e0179330. [CrossRef] [PubMed]eng
dcterms.referencesPrasad, K.; Dhar, I.; Caspar-Bell, G. Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease. Int. J. Angiol. 2015, 24, 75–80. [CrossRef] [PubMed]eng
dcterms.referencesKim, C.-S.; Park, S.; Kim, J. The Role of Glycation in the Pathogenesis of Aging and Its Prevention through Herbal Products and Physical Exercise. J. Exerc. Nutr. Biochem. 2017, 21, 55–61. [CrossRef] [PubMed]eng
dcterms.referencesBorg, D.J.; Forbes, J.M. Targeting Advanced Glycation with Pharmaceutical Agents: Where Are We Now? Glycoconj. J. 2016, 33, 653–670. [CrossRef]eng
dcterms.referencesGarg, S.; Syngle, A.; Vohra, K. Efficacy and Tolerability of Advanced Glycation End-Products Inhibitor in Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Study. Clin. J. Pain. 2013, 29, 717–724. [CrossRef]eng
dcterms.referencesMirmiranpour, H.; Mousavizadeh, M.; Noshad, S.; Ghavami, M.; Ebadi, M.; Ghasemiesfe, M.; Nakhjavani, M.; Esteghamati, A. Comparative Effects of Pioglitazone and Metformin on Oxidative Stress Markers in Newly Diagnosed Type 2 Diabetes Patients: A Randomized Clinical Trial. J. Diabetes Complicat. 2013, 27, 501–507. [CrossRef]eng
dcterms.referencesDerosa, G.; Bonaventura, A.; Romano, D.; Bianchi, L.; Fogari, E.; D’Angelo, A.; Maffioli, P. Enalapril/Lercanidipine Combination on Markers of Cardiovascular Risk: A Randomized Study. J. Am. Soc. Hypertens. 2014, 8, 422–428. [CrossRef]eng
dcterms.referencesContreras, C.L.; Guzman-Rosiles, I.; Castillo, D.D.; Gomez-Ojeda, A.; Garay-Sevilla, M.E. Advanced Glycation End Products (AGEs) and SRAGE Levels after Benfotiamine Treatment in Diabetes Mellitus Type 2. FASEB J. 2017, 31, 646.32. [CrossRef]eng
dcterms.referencesFujimoto, N.; Hastings Jeffrey, L.; Carrick-Ranson, G.; Shafer Keri, M.; Shibata, S.; Bhella Paul, S.; Abdullah Shuaib, M.; Barkley Kyler, W.; Adams-Huet, B.; Boyd Kara, N.; et al. Cardiovascular Effects of 1 Year of Alagebrium and Endurance Exercise Training in Healthy Older Individuals. Circ. Heart Fail. 2013, 6, 1155–1164. [CrossRef] [PubMed]eng
dcterms.referencesOudegeest-Sander, M.H.; Rikkert, M.G.M.O.; Smits, P.; Thijssen, D.H.J.; van Dijk, A.P.J.; Levine, B.D.; Hopman, M.T.E. The Effect of an Advanced Glycation End-Product Crosslink Breaker and Exercise Training on Vascular Function in Older Individuals: A Randomized Factorial Design Trial. Exp. Gerontol. 2013, 48, 1509–1517. [CrossRef] [PubMed]eng
dcterms.referencesYubero-Serrano, E.M.; Woodward, M.; Poretsky, L.; Vlassara, H.; Striker, G.E. AGE-less Study Group Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/pro-Oxidant Status in Patients with Diabetic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2015, 10, 759–766. [CrossRef]eng
dcterms.referencesUeda, S.; Yamagishi, S.; Takeuchi, M.; Kohno, K.; Shibata, R.; Matsumoto, Y.; Kaneyuki, U.; Fujimura, T.; Hayashida, A.; Okuda, S. Oral Adsorbent AST–120 Decreases Serum Levels of AGEs in Patients with Chronic Renal Failure. Mol. Med. 2006, 12, 180–184. [CrossRef] [PubMed]eng
dcterms.referencesSchulman, G.; Berl, T.; Beck, G.J.; Remuzzi, G.; Ritz, E.; Arita, K.; Kato, A.; Shimizu, M. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J. Am. Soc. Nephrol. 2015, 26, 1732–1746. [CrossRef]eng
dcterms.referencesYamagishi, S.; Nakamura, K.; Matsui, T.; Inoue, H.; Takeuchi, M. Oral Administration of AST-120 (Kremezin) Is a Promising Therapeutic Strategy for Advanced Glycation End Product (AGE)-Related Disorders. Med. Hypotheses 2007, 69, 666–668. [CrossRef]eng
dcterms.referencesHabbous, S.; Przech, S.; Acedillo, R.; Sarma, S.; Garg, A.X.; Martin, J. The Efficacy and Safety of Sevelamer and Lanthanum versus Calcium-Containing and Iron-Based Binders in Treating Hyperphosphatemia in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Nephrol. Dial. Transpl. 2017, 32, 111–125. [CrossRef]eng
dcterms.referencesVlassara, H.; Uribarri, J.; Cai, W.; Goodman, S.; Pyzik, R.; Post, J.; Grosjean, F.; Woodward, M.; Striker, G.E. Effects of Sevelamer on HbA1c, Inflammation, and Advanced Glycation End Products in Diabetic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2012, 7, 934–942. [CrossRef] [PubMed]eng
dcterms.referencesEdelstein, D.; Brownlee, M. Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine. Diabetes 1992, 41, 26–29. [CrossRef]eng
dcterms.referencesBrownlee, M.; Vlassara, H.; Kooney, A.; Ulrich, P.; Cerami, A. Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking. Science 1986, 232, 1629–1632. [CrossRef] [PubMed]eng
dcterms.referencesJoglekar, M.M.; Bavkar, L.N.; Sistla, S.; Arvindekar, A.U. Effective Inhibition of Protein Glycation by Combinatorial Usage of Limonene and Aminoguanidine through Differential and Synergistic Mechanisms. Int. J. Biol. Macromol. 2017, 99, 563–569. [CrossRef]eng
dcterms.referencesThornalley, P.J. Use of Aminoguanidine (Pimagedine) to Prevent the Formation of Advanced Glycation Endproducts. Arch Biochem Biophys 2003, 419, 31–40. [CrossRef] [PubMed]eng
dcterms.referencesSoulis-Liparota, T.; Cooper, M.; Papazoglou, D.; Clarke, B.; Jerums, G. Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat. Diabetes 1991, 40, 1328–1334. [CrossRef] [PubMed]eng
dcterms.referencesYagihashi, S.; Kamijo, M.; Baba, M.; Yagihashi, N.; Nagai, K. Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats. Diabetes 1992, 41, 47–52. [CrossRef]eng
dcterms.referencesSampath, C.; Zhu, Y.; Sang, S.; Ahmedna, M. Bioactive Compounds Isolated from Apple, Tea, and Ginger Protect against Dicarbonyl Induced Stress in Cultured Human Retinal Epithelial Cells. Phytomedicine 2016, 23, 200–213. [CrossRef]eng
dcterms.referencesTanaka, Y.; Uchino, H.; Shimizu, T.; Yoshii, H.; Niwa, M.; Ohmura, C.; Mitsuhashi, N.; Onuma, T.; Kawamori, R. Effect of Metformin on Advanced Glycation Endproduct Formation and Peripheral Nerve Function in Streptozotocin-Induced Diabetic Rats. Eur. J. Pharm. 1999, 376, 17–22. [CrossRef]eng
dcterms.referencesEngelen, L.; Stehouwer, C.D.A.; Schalkwijk, C.G. Current Therapeutic Interventions in the Glycation Pathway: Evidence from Clinical Studies. Diabetes Obes. Metab. 2013, 15, 677–689. [CrossRef]eng
dcterms.referencesJang, D.S.; Kim, J.M.; Kim, J.; Yoo, J.L.; Kim, Y.S.; Kim, J.S. Effects of Compounds Isolated from the Fruits of Rumex Japonicus on the Protein Glycation. Chem. Biodivers. 2008, 5, 2718–2723. [CrossRef]eng
dcterms.referencesStarowicz, M.; Zieli ´nski, H. Inhibition of Advanced Glycation End-Product Formation by High Antioxidant-Leveled Spices Commonly Used in European Cuisine. Antioxidants 2019, 8, 100. [CrossRef]eng
dcterms.referencesGugliucci, A.; Bastos, D.H.M.; Schulze, J.; Souza, M.F.F. Caffeic and Chlorogenic Acids in Ilex Paraguariensis Extracts Are the Main Inhibitors of AGE Generation by Methylglyoxal in Model Proteins. Fitoterapia 2009, 80, 339–344. [CrossRef]eng
dcterms.references. Perez Gutierrez, R.M.; Flores Cotera, L.B.; Gonzalez, A.M.N. Evaluation of the Antioxidant and Anti-Glication Effects of the Hexane Extract from Piper Auritum Leaves in Vitro and Beneficial Activity on Oxidative Stress and Advanced Glycation End-Product-Mediated Renal Injury in Streptozotocin-Treated Diabetic Rats. Molecules 2012, 17, 1897. [CrossRef] [PubMed]eng
dcterms.referencesYeh, W.-J.; Hsia, S.-M.; Lee, W.-H.; Wu, C.-H. Polyphenols with Antiglycation Activity and Mechanisms of Action: A Review of Recent Findings. J. Food Drug Anal. 2017, 25, 84–92. [CrossRef] [PubMed]eng
dcterms.referencesWang, W.; Yang, R.; Yao, H.; Wu, Y.; Pan, W.; Jia, A.-Q. Inhibiting the Formation of Advanced Glycation End-Products by Three Stilbenes and the Identification of Their Adducts. Food Chem. 2019, 295, 10–15. [CrossRef] [PubMed]eng
dcterms.referencesFerrannini, E. The Target of Metformin in Type 2 Diabetes. N. Engl. J. Med. 2014, 371, 1547–1548. [CrossRef] [PubMed]eng
dcterms.referencesDiaz-Morales, N.; Rovira-Llopis, S.; Bañuls, C.; Lopez-Domenech, S.; Escribano-Lopez, I.; Veses, S.; Jover, A.; Rocha, M.; Hernandez-Mijares, A.; Victor, V.M. Does Metformin Protect Diabetic Patients from Oxidative Stress and Leukocyte-Endothelium Interactions? Antioxid. Redox Signal 2017, 27, 1439–1445. [CrossRef]eng
dcterms.referencesEsteghamati, A.; Eskandari, D.; Mirmiranpour, H.; Noshad, S.; Mousavizadeh, M.; Hedayati, M.; Nakhjavani, M. Effects of Metformin on Markers of Oxidative Stress and Antioxidant Reserve in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized Clinical Trial. Clin. Nutr. 2013, 32, 179–185. [CrossRef]eng
dcterms.referencesRuggiero-Lopez, D.; Lecomte, M.; Moinet, G.; Patereau, G.; Lagarde, M.; Wiernsperger, N. Reaction of Metformin with Dicarbonyl Compounds. Possible Implication in the Inhibition of Advanced Glycation End Product Formation. Biochem. Pharm. 1999, 58, 1765–1773. [CrossRef]eng
dcterms.referencesAdeshara, K.; Tupe, R. Antiglycation and Cell Protective Actions of Metformin and Glipizide in Erythrocytes and Monocytes. Mol. Biol. Rep. 2016, 43, 195–205. [CrossRef]eng
dcterms.referencesMetz, T.O.; Alderson, N.L.; Thorpe, S.R.; Baynes, J.W. Pyridoxamine, an Inhibitor of Advanced Glycation and Lipoxidation Reactions: A Novel Therapy for Treatment of Diabetic Complications. Arch. Biochem. Biophys. 2003, 419, 41–49. [CrossRef]eng
dcterms.referencesHammes, H.-P.; Du, X.; Edelstein, D.; Taguchi, T.; Matsumura, T.; Ju, Q.; Lin, J.; Bierhaus, A.; Nawroth, P.; Hannak, D.; et al. Benfotiamine Blocks Three Major Pathways of Hyperglycemic Damage and Prevents Experimental Diabetic Retinopathy. Nat. Med. 2003, 9, 294–299. [CrossRef] [PubMed]eng
dcterms.referencesVoziyan, P.A.; Hudson, B.G. Pyridoxamine as a Multifunctional Pharmaceutical: Targeting Pathogenic Glycation and Oxidative Damage. Cell Mol. Life Sci. 2005, 62, 1671–1681. [CrossRef] [PubMed]eng
dcterms.referencesDeluyker, D.; Ferferieva, V.; Driesen, R.B.; Verboven, M.; Lambrichts, I.; Bito, V. Pyridoxamine Improves Survival and Limits Cardiac Dysfunction after MI. Sci. Rep. 2017, 7, 1–12. [CrossRef]eng
dcterms.referencesPereira, A.; Fernandes, R.; Crisóstomo, J.; Seiça, R.M.; Sena, C.M. The Sulforaphane and Pyridoxamine Supplementation Normalize Endothelial Dysfunction Associated with Type 2 Diabetes. Sci. Rep. 2017, 7, 14357. [CrossRef]eng
dcterms.referencesNagai, R.; Murray, D.B.; Metz, T.O.; Baynes, J.W. Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications. Diabetes 2012, 61, 549–559. [CrossRef] [PubMed]eng
dcterms.referencesVistoli, G.; De Maddis, D.; Cipak, A.; Zarkovic, N.; Carini, M.; Aldini, G. Advanced Glycoxidation and Lipoxidation End Products (AGEs and ALEs): An Overview of Their Mechanisms of Formation. Free Radic. Res. 2013, 47 (Suppl. 1), 3–27. [CrossRef]eng
dcterms.referencesŠebeková, K.; Schinzel, R.; Münch, G.; Krivošíková, Z.; Dzúrik, R.; Heidland, A. Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan. MEM 1999, 25, 380–383. [CrossRef] [PubMed]eng
dcterms.referencesMonacelli, F.; Poggi, A.; Storace, D.; Durante, A.; Traverso, N.; Viviani, G.L.; Odetti, P. Effects of Valsartan Therapy on Protein Glycoxidation. Metabolism 2006, 55, 1619–1624. [CrossRef]eng
dcterms.references. Miyata, T.; van Ypersele de Strihou, C. Angiotensin II Receptor Blockers and Angiotensin Converting Enzyme Inhibitors: Implication of Radical Scavenging and Transition Metal Chelation in Inhibition of Advanced Glycation End Product Formation. Arch. Biochem. Biophys. 2003, 419, 50–54. [CrossRef]eng
dcterms.referencesChang, P.-C.; Tsai, S.-C.; Chong, L.Y.; Kao, M.-J. N-Phenacylthiazolium Bromide Inhibits the Advanced Glycation End Product (AGE)-AGE Receptor Axis to Modulate Experimental Periodontitis in Rats. J. Periodontol. 2014, 85, e268–e276. [CrossRef] [PubMed]eng
dcterms.referencesWolffenbuttel, B.H.R.; Boulanger, C.M.; Crijns, F.R.L.; Huijberts, M.S.P.; Poitevin, P.; Swennen, G.N.M.; Vasan, S.; Egan, J.J.; Ulrich, P.; Cerami, A.; et al. Breakers of Advanced Glycation End Products Restore Large Artery Properties in Experimental Diabetes. Proc. Natl. Acad. Sci. USA 1998, 95, 4630–4634. [CrossRef]eng
dcterms.referencesVasan, S.; Zhang, X.; Zhang, X.; Kapurniotu, A.; Bernhagen, J.; Teichberg, S.; Basgen, J.; Wagle, D.; Shih, D.; Terlecky, I.; et al. An Agent Cleaving Glucose-Derived Protein Crosslinks in Vitro and in Vivo. Nature 1996, 382, 275–278. [CrossRef] [PubMed]eng
dcterms.referencesBradke, B.S.; Vashishth, D. N-Phenacylthiazolium Bromide Reduces Bone Fragility Induced by Nonenzymatic Glycation. PLoS ONE 2014, 9, e103199. [CrossRef] [PubMed]eng
dcterms.referencesKim, N.Y.; Goddard, T.N.; Sohn, S.; Spiegel, D.A.; Crawford, J.M. Biocatalytic Reversal of Advanced Glycation End Product Modification. Chembiochem 2019, 20, 2402–2410. [CrossRef]eng
dcterms.referencesBakris, G.L.; Bank, A.J.; Kass, D.A.; Neutel, J.M.; Preston, R.A.; Oparil, S. Advanced Glycation End-Product Cross-Link Breakers. A Novel Approach to Cardiovascular Pathologies Related to the Aging Process. Am. J. Hypertens. 2004, 17, 23S–30S. [CrossRef] [PubMed]eng
dcterms.referencesWatson, A.M.D.; Soro-Paavonen, A.; Sheehy, K.; Li, J.; Calkin, A.C.; Koitka, A.; Rajan, S.N.; Brasacchio, D.; Allen, T.J.; Cooper, M.E.; et al. Delayed Intervention with AGE Inhibitors Attenuates the Progression of Diabetes-Accelerated Atherosclerosis in Diabetic Apolipoprotein E Knockout Mice. Diabetologia 2011, 54, 681–689. [CrossRef]eng
dcterms.referencesKranstuber, A.L.; Del Rio, C.; Biesiadecki, B.J.; Hamlin, R.L.; Ottobre, J.; Gyorke, S.; Lacombe, V.A. Advanced Glycation End Product Cross-Link Breaker Attenuates Diabetes-Induced Cardiac Dysfunction by Improving Sarcoplasmic Reticulum Calcium Handling. Front. Physiol. 2012, 3, 292. [CrossRef]eng
dcterms.referencesZhang, B.; He, K.; Chen, W.; Cheng, X.; Cui, H.; Zhong, W.; Li, S.; Wang, L. Alagebrium (ALT-711) Improves the Anti-Hypertensive Efficacy of Nifedipine in Diabetic-Hypertensive Rats. Hypertens. Res. 2014, 37, 901–907. [CrossRef]eng
dcterms.referencesSusic, D.; Varagic, J.; Frohlich, E.D. Cardiovascular and Renal Effects of a Collagen Cross-Link Breaker (ALT 711) in Adult and Aged Spontaneously Hypertensive Rats. Am. J. Hypertens. 2004, 17, 328–333. [CrossRef]eng
dcterms.referencesDozio, E.; Vianello, E.; Bandera, F.; Longhi, E.; Brizzola, S.; Nebuloni, M.; Corsi Romanelli, M.M. Soluble Receptor for Advanced Glycation End Products: A Protective Molecule against Intramyocardial Lipid Accumulation in Obese Zucker Rats? Mediat. Inflamm. 2019, 2019. [CrossRef]eng
dcterms.referencesKoyama, H.; Yamamoto, H.; Nishizawa, Y. RAGE and Soluble RAGE: Potential Therapeutic Targets for Cardiovascular Diseases. Mol. Med. 2007, 13, 625–635. [CrossRef]eng
dcterms.referencesXu, L.; Zang, P.; Feng, B.; Qian, Q. Atorvastatin Inhibits the Expression of RAGE Induced by Advanced Glycation End Products on Aortas in Healthy Sprague-Dawley Rats. Diabetol. Metab. Syndr. 2014, 6, 102. [CrossRef] [PubMed]eng
dcterms.referencesCuccurullo, C.; Iezzi, A.; Fazia, M.L.; De Cesare, D.; Di Francesco, A.; Muraro, R.; Bei, R.; Ucchino, S.; Spigonardo, F.; Chiarelli, F.; et al. Suppression of RAGE as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes. Arter. Thromb. Vasc. Biol. 2006, 26, 2716–2723. [CrossRef] [PubMed]eng
dcterms.referencesMarx, N.; Walcher, D.; Ivanova, N.; Rautzenberg, K.; Jung, A.; Friedl, R.; Hombach, V.; de Caterina, R.; Basta, G.; Wautier, M.-P.; et al. Thiazolidinediones Reduce Endothelial Expression of Receptors for Advanced Glycation End Products. Diabetes 2004, 53, 2662–2668. [CrossRef]eng
dcterms.referencesSirtori, C.R. The Pharmacology of Statins. Pharm. Res. 2014, 88, 3–11. [CrossRef]eng
dcterms.referencesSoccio, R.E.; Chen, E.R.; Lazar, M.A. Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes. Cell Metab. 2014, 20, 573–591. [CrossRef] [PubMed]eng
dcterms.references. Chen, M.; Li, H.; Wang, G.; Shen, X.; Zhao, S.; Su, W. Atorvastatin Prevents Advanced Glycation End Products (AGEs)-Induced Cardiac Fibrosis via Activating Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ). Metabolism 2016, 65, 441–453. [CrossRef]eng
dcterms.referencesChiang, M.-C.; Cheng, Y.-C.; Nicol, C.J.; Lin, C.-H. The Neuroprotective Role of Rosiglitazone in Advanced Glycation End Product Treated Human Neural Stem Cells Is PPARgamma-Dependent. Int. J. Biochem. Cell Biol. 2017, 92, 121–133. [CrossRef]eng
dcterms.referencesSabbagh, M.N.; Agro, A.; Bell, J.; Aisen, P.S.; Schweizer, E.; Galasko, D. PF-04494700, an Oral Inhibitor of Receptor For Advanced Glycation End Products (RAGE), in Alzheimer’s Disease. Alzheimer. Dis. Assoc. Disord. 2011, 25, 206–212. [CrossRef] [PubMed]eng
dcterms.referencesBurstein, A.H.; Grimes, I.; Galasko, D.R.; Aisen, P.S.; Sabbagh, M.; Mjalli, A.M.M. Effect of TTP488 in Patients with Mild to Moderate Alzheimer’s Disease. BMC Neurol. 2014, 14, 12. [CrossRef] [PubMed]eng
dcterms.referencesZong, H.; Ward, M.; Stitt, A.W. AGEs, RAGE, and Diabetic Retinopathy. Curr. Diab. Rep. 2011, 11, 244–252. [CrossRef]eng
dcterms.referencesChen, S.; Yin, L.; Xu, Z.; An, F.-M.; Liu, A.-R.; Wang, Y.; Yao, W.-B.; Gao, X.-D. Inhibiting Receptor for Advanced Glycation End Product (AGE) and Oxidative Stress Involved in the Protective Effect Mediated by Glucagon-like Peptide-1 Receptor on AGE Induced Neuronal Apoptosis. Neurosci. Lett. 2016, 612, 193–198. [CrossRef] [PubMed]eng
dcterms.referencesZhang, S.-S.; Wu, Z.; Zhang, Z.; Xiong, Z.-Y.; Chen, H.; Huang, Q.-B. Glucagon-like Peptide-1 Inhibits the Receptor for Advanced Glycation Endproducts to Prevent Podocyte Apoptosis Induced by Advanced Oxidative Protein Products. Biochem. Biophys. Res. Commun. 2017, 482, 1413–1419. [CrossRef] [PubMed]eng
dcterms.referencesDorecka, M.; Siemianowicz, K.; Francuz, T.; Garczorz, W.; Chyra, A.; Klych, A.; Romaniuk, W. Exendin-4 and GLP-1 Decreases Induced Expression of ICAM-1, VCAM-1 and RAGE in Human Retinal Pigment Epithelial Cells. Pharm. Rep. 2013, 65, 884–890. [CrossRef]eng
dcterms.referencesZhan, Y.; Sun, H.; Chen, H.; Zhang, H.; Sun, J.; Zhang, Z.; Cai, D. Glucagon-like Peptide-1 (GLP-1) Protects Vascular Endothelial Cells against Advanced Glycation End Products (AGEs) Induced Apoptosis. Med. Sci. Monit. 2012, 18, BR286–BR291. [CrossRef]eng
dcterms.referencesYi, B.; Hu, X.; Wen, Z.; Zhang, T.; Cai, Y. Exendin-4, a Glucagon-like Peptide-1 Receptor Agonist, Inhibits Hyperglycemia-induced Apoptosis in Myocytes by Suppressing Receptor for Advanced Glycation End Products Expression. Exp. Ther. Med. 2014, 8, 1185–1190. [CrossRef]eng
dcterms.referencesBolton, W.K.; Cattran, D.C.; Williams, M.E.; Adler, S.G.; Appel, G.B.; Cartwright, K.; Foiles, P.G.; Freedman, B.I.; Raskin, P.; Ratner, R.E.; et al. Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy. Am. J. Nephrol. 2004, 24, 32–40. [CrossRef]eng
dcterms.referencesSuji, G.; Sivakami, S. DNA Damage by Free Radical Production by Aminoguanidine. Ann. N. Y. Acad. Sci. 2006, 1067, 191–199. [CrossRef]eng
dcterms.referencesTilton, R.G.; Chang, K.; Hasan, K.S.; Smith, S.R.; Petrash, J.M.; Misko, T.P.; Moore, W.M.; Currie, M.G.; Corbett, J.A.; McDaniel, M.L. Prevention of Diabetic Vascular Dysfunction by Guanidines. Inhibition of Nitric Oxide Synthase versus Advanced Glycation End-Product Formation. Diabetes 1993, 42, 221–232. [CrossRef]eng
dcterms.referencesSakata, K.; Hayakawa, M.; Yano, Y.; Tamaki, N.; Yokota, N.; Eto, T.; Watanabe, R.; Hirayama, N.; Matsuo, T.; Kuroki, K.; et al. Efficacy of Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Glucose Parameters, the Activity of the Advanced Glycation End Product (AGE) Receptor for AGE (RAGE) Axis and Albuminuria in Japanese Type 2 Diabetes. Diabetes Metab. Res. Rev. 2013, 29, 624–630. [CrossRef] [PubMed]eng
dcterms.referencesKoyama, H.; Tanaka, S.; Monden, M.; Shoji, T.; Morioka, T.; Fukumoto, S.; Mori, K.; Emoto, M.; Shoji, T.; Fukui, M.; et al. Comparison of Effects of Pioglitazone and Glimepiride on Plasma Soluble RAGE and RAGE Expression in Peripheral Mononuclear Cells in Type 2 Diabetes: Randomized Controlled Trial (PioRAGE). Atherosclerosis 2014, 234, 329–334. [CrossRef]eng
dcterms.references. Liu, J.-S.; Chuang, T.-J.; Chen, J.-H.; Lee, C.-H.; Hsieh, C.-H.; Lin, T.-K.; Hsiao, F.-C.; Hung, Y.-J. Cilostazol Attenuates the Severity of Peripheral Arterial Occlusive Disease in Patients with Type 2 Diabetes: The Role of Plasma Soluble Receptor for Advanced Glycation End-Products. Endocrine 2015, 49, 703–710. [CrossRef] [PubMed]eng
dcterms.referencesPeng, Y.; Park, H.-S.; Tang, L.A.; Horwitz, N.; Lin, L. Generation of SRAGEhigh Transgenic Mice to Study Inflammaging. Front. Biosci. 2019, 24, 555–563.eng
dcterms.referencesWang, B.-J.; Qian, L.; Li, J.; Wang, F.; Yang, Q.-L.; Li, G.; Liang, Y.-L.; Guo, Y.-H. SRAGE Plays a Role as a Protective Factor in the Development of PCOS by Inhibiting Inflammation. Gynecol. Endocrinol. 2020, 36, 148–151. [CrossRef]eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
AGeP_New-clinical-and-molecular-perspectives.pdf
Tamaño:
4.3 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca